Research study for Adults with Non-Alcoholic Steatohepatitis (NASH) cirrhosis


16483

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Medicine

Caldwell Stephen, H

UVa Health System Division of Gastroenterology seeks adults ages 18-65 with Non-Alcoholic Steatohepatitis (NASH) cirrhosis for research study. The purpose of the study is to determine if an investigational drug called GS-6624 is effective at treating NASH (fatty liver disease) especially in stopping or reversing fibrosis (buildup of scar tissue in the liver). All study-related procedures and medication provided free of charge. Compensation for study visits provided For more information please contact: • Jennifer A. Greene, RN • 434-982-0709 or jag7fh@virginia.edu • Insert IRB-HSR # 16483 Principal Investigator: Stephen Caldwell, MD

Gastroenterology & Hepatology (Digestive Health)

Adult

Non-Alcoholic Steatohepatitis (NASH)
Liver Disease

Gastroenterology/Hepatology

Ill

Compensation for study visits provided

Jennifer Greene

jag7fh@virginia.edu

4349820709